Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Source filing unavailable
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $154.60M | $195.10M | $216.80M | $173.20M |
| Net Income | -$37.90M | -$8.30M | $2.60M | $15.30M |
| EPS Diluted | -$0.50 | -$0.11 | $0.03 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
